血清MIA检测在恶性黑素瘤诊断中的临床价值

The clinical value of quantitated serum levels of MIA protein in diagnosis of malignant melanomas

目的 :探讨血清黑素瘤抑制蛋白 (melonom a- inhibiting activity protein,MIA)在恶性黑素瘤诊断中的价值。方法 :采用 EL ISA方法 ,检测不同临床分期的黑素瘤及其他恶性肿瘤患者 ,以及正常人血清 MIA浓度。 结果 :正常成人 (n=2 0 )和肺癌 (n=10 )、肝癌 (n=12 )、结肠癌 (n=12 )患者血清 MIA浓度全部低于正常 (6 .5 ng/m l)水平 ,黑素瘤患者血清 MIA浓度明显升高 ,阳性率达 77.3% (17/2 2 ) ,其中 , 期患者阳性率达 10 0 % (15 /15 )。乳腺癌患者阳性率 2 6 .7% (4/15 )。 结论 :血清MIA水平是临床诊断黑素瘤的一个较好指标。

Objective: To determine clinical value of serum melanoma inhibiting activity(MIA) in patients with malignant melanomas. Methods: The serum levels of MIA were detected by means of a nonradioactive ELISA. Results: The enhanced MIA serum levels were detected in 26.7%(4/15) of patients with breast cancer, and in 77.3% (17/22) of patients with melanoma, of which 100% (15/15) were patients with stage Ⅲ or stage Ⅳ melanoma. Conclusion: MIA represents a novel serum marker for advanced malignant melanoma revealing the highest sensitivity and specificity among currently avaliable markers.